+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Orexin Receptor Type 1 - Pipeline Review, H2 2019

  • ID: 4900216
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 78 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Chronos Therapeutics Ltd
  • Eisai Co Ltd
  • Eolas Therapeutics Inc
  • Indivior Plc
  • Inexia Ltd
  • Johnson & Johnson
  • MORE
Orexin Receptor Type 1 - Pipeline Review, H2 2019

Summary

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) pipeline Target constitutes close to 14 molecules. The latest report Orexin Receptor Type 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Orexin receptor type 1 (Ox1R or OX1) is a protein that is encoded by the HCRTR1 gene. The orexin 1 receptor (OX1) is a G-protein coupled receptor that is highly expressed in projections from the lateral hypothalamus and is involved in the regulation of feeding behavior. OX1 selectively binds the orexin-A neuropeptide. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 2, 7 and 1 respectively. Report covers products from therapy areas Central Nervous System and Respiratory which include indications Binge Eating Disorder, Nicotine Addiction, Insomnia, Addiction, Alcohol Addiction, Drug Addiction, Obstructive Sleep Apnea, Anxiety Disorders, Dementia Associated With Alzheimer's Disease, Major Depressive Disorder, Narcolepsy, Opioid Use Disorder, Panic Disorders, Parkinson's Disease, Pathological Gambling, Sleep Disorders and Smoking Cessation.

Furthermore, this report also reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)
  • The report reviews Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Chronos Therapeutics Ltd
  • Eisai Co Ltd
  • Eolas Therapeutics Inc
  • Indivior Plc
  • Inexia Ltd
  • Johnson & Johnson
  • MORE
Introduction
Report Coverage
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Overview
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Companies Involved in Therapeutics Development
Chronos Therapeutics Ltd
Eisai Co Ltd
Eolas Therapeutics Inc
Idorsia Pharmaceutical Ltd
Indivior Plc
Inexia Ltd
Johnson & Johnson
OXonium Therapeutics
Sosei Heptares
Yangtze River Pharmaceutical Group
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Drug Profiles
ACT-539313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-010018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize Ox1 Receptor for Binge Eating Disorder - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EORA-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INDV-2000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-3215 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lemborexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nemorexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPN-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Orexin-1 Receptor for Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Mollecules to Antagonize HCRTR1 for Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
suvorexant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YZJ-1139 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Dormant Products
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Discontinued Products
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Product Development Milestones
Featured News & Press Releases
Dec 10, 2019: Eisai presents new findings on Lemborexant as potential Sleep-Wake disorder therapy at 12th Clinical Trials on Alzheimer's Disease (CTAD) conference
Dec 09, 2019: Altasciences to conduct clinical trial for Opioid Use Disorder under NIH funding
Dec 02, 2019: Eisai to present latest data on lemborexant at 12th Clinical Trials on Alzheimer’s Disease Conference
Nov 22, 2019: A sleeping pill that doesn’t make you sway: a new targeted insomnia treatment
Oct 24, 2019: Trial to test insomnia drug for alcohol use disorder
Sep 27, 2019: Three new analyses of data expand understanding of the potential role for investigational agent Lemborexant in Insomnia and Irregular Sleep-Wake Rhythm Disorder
Sep 26, 2019: Announcement of National Institutes of Health (NIH) grant award through the NIH helping to end addiction long-term (HEAL) initiative
Sep 19, 2019: Eisai to present latest data on Lemborexant at World Sleep Congress
Jul 11, 2019: Latest data on Eisai's lemborexant to be presented at Alzheimer’s Association International Conference (AAIC) 2019
Jun 13, 2019: Efficacy and safety data with Idorsias dual orexin receptor antagonist presented at SLEEP 2019 in San Antonio
Jun 11, 2019: Extensive analyses of phase 3 data for investigational Lemborexant assess efficacy and safety profile for the potential treatment of insomnia in adults
May 28, 2019: Eisai to present eight Lemborexant posters at SLEEP 2019 meeting, Including new pooled analyses from phase 3 studies and new phase 1 data
May 09, 2019: Merck’s Belsomra achieves Phase III efficacy endpoints for insomnia
Apr 24, 2019: Eisai to present on lemborexant at the 2019 American Academy of Neurology Annual Meeting
Mar 11, 2019: Eisai and Imbrium Therapeutics announce U.S. FDA filing acceptance of New Drug Application for lemborexant for the treatment of insomnia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Chronos Therapeutics Ltd, H2 2019
Pipeline by Eisai Co Ltd, H2 2019
Pipeline by Eolas Therapeutics Inc, H2 2019
Pipeline by Idorsia Pharmaceutical Ltd, H2 2019
Pipeline by Indivior Plc, H2 2019
Pipeline by Inexia Ltd, H2 2019
Pipeline by Johnson & Johnson, H2 2019
Pipeline by OXonium Therapeutics, H2 2019
Pipeline by Sosei Heptares, H2 2019
Pipeline by Yangtze River Pharmaceutical Group, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Chronos Therapeutics Ltd
  • Eisai Co Ltd
  • Eolas Therapeutics Inc
  • Idorsia Pharmaceutical Ltd
  • Indivior Plc
  • Inexia Ltd
  • Johnson & Johnson
  • OXonium Therapeutics
  • Sosei Heptares
  • Yangtze River Pharmaceutical Group
Note: Product cover images may vary from those shown
Adroll
adroll